Heptares Therapeutics is a drug discovery company focused on novel small-molecule drugs targeting G-protein-coupled receptors (GPCRs), the largest family of druggable targets.The Company has developed a unique, transformational and proprietary technology for making purified, stabilised and functional GPCRs (known as StaRs, StabilisedReceptors), overcoming a major limiting factor to the development of new drugs targeting this group.

Biotechnology

Pharmaceutical

Therapeutics

Heptares Therapeutics

Chris Cargill

Mariko Nakafuji

Takuya Saiki

Shinichiro N.

Nigel Swain

Matthew Foxwell

Matt Barnes

Mathieu Rappas

Kieran Johnson

Jayesh Patel

Hironoshin Nomura

Helen Carberry

Gerry McAnally

Gareth Waldron

Chris de Graaf

Candelle Chong

The Finance & Accounting team at Heptares Therapeutics is responsible for managing the financial health of the company, ensuring accurate financial reporting, budgeting, and compliance. This team oversees financial transactions, prepares financial statements, and provides insights to support strategic decision-making, ultimately contributing to the company’s mission of advancing drug discovery and development.

Finance & Accounting

Research and Development Scientists

Leadership Team

Finance & Accounting

About

Team members

Other teams at Heptares Therapeutics

Research and Development Scientists

Leadership Team